For non-oral dosage forms, public plans generally pay 75% to 85% of the brand price for the first generic, dropping to around 50% once a second product is listed and to roughly 35% when three or more generics are available
Lancet 1:200204 Dahl-Jrgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O (1985) Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study
To understand how we are getting these longer-term effects, we need to study these drugs on a longer time scaleand thats exactly what we did. When the hormone GLP-1 finds a pancreatic beta cell, the ensuing chain of signals, proteins, and gene expression changes that lead to insulin secretion is very well documented
doi: 10.21926/obm.geriatr.2002123 5 DaviesMJD'AlessioDAFradkinJKernanWNMathieuCMingroneGet al
I'm grateful for the time and money being poured into potential treatments and cures for Type 1 Diabetes and the huge progress made so far with insulin pumps and hybrid closed loop systems
